Scholars Academic Journal of Pharmacy (SAJP)

Sch. Acad. J. Pharm., 2015; 4(7): 337-339 ©Scholars Academic and Scientific Publisher (An International Publisher for Academic and Scientific Resources) www.saspublisher.com

ISSN 2320-4206 (Online) ISSN 2347-9531 (Print)

Research Article

Estimation of Serum Uric Acid and Bilirubin in Breast Cancer

Dr R J Chhabra¹, Dr. Ketan Mangukiya¹, Mrs Neha Sharma², Miss Ritu Sharma² ¹Department of Biochemistry, Parul Institute of medical science and Research (PIMSR), Vadodara, Gujarat, India ²Department of Biochemistry, Geetanjali medical college and Hospital, Udaipur, Rajasthan, India.

*Corresponding author Dr R J Chhabra Email: <u>dr.ketan.mangukiya@gmail.com</u>

Abstract: High level of serum uric acid is important in diagnosis, cancer risk, recurrence and medical management of breast carcinoma. Serum uric acid provides a primary defense against human cancer based upon its capacity to scavenge singlet oxygen and its capacity to inhibit lipid per oxidation. To estimate Level of Serum Uric acid and Bilirubin in Breast cancer patients. The study includes 50 patients of breast cancer of 20-70 year age group along with age and sex matched healthy control. Serum Uric acid and Bilirubin was estimated from all participant and obtained data were analysed statistically by calculating p-value. In results the mean uric acid level increases (8.6 +1.3) with S.D. in study population and found to be significant (p<0.050) when compared to healthy control group uric acid level (mean+S.D. = 4.9 + 1.6). Bilirubin level were found to be 0.93 + 1.4 (mean+S.D.) in breast carcinoma patients while in healthy it was 0.86 + 2.6 S.D.(mean+ S.D.) and showed insignificant correlation when compared with control group (p=0.86). in conclusion the increased uric acid level may be a diagnostic marker in breast carcinoma as well as it showed oxidative stress in breast carcinoma and role of uric acid as antioxidant. However bilirubin level within normal limits in both groups showed role of bilirubin insignificant in breast cancer. **Keywords:** Breast carcinoma, Uric acid, Bilirubin.

INTRODUCTION

Although uric acid can act as an antioxidant, excess serum accumulation is often associated with cardiovascular disease. It is not known whether this is causative (e.g., by acting as a pro oxidant) or a protective reaction taking advantage of urate's antioxidant properties. The same may account for the putative role of uric acid in the etiology of stroke [1, 2]. Uric acid can act as a pro oxidant and it may thus be a marker of oxidative stress, but it may also have a therapeutic role as an antioxidant [3, 4]. Urate, the soluble form of uric acid, can scavenge the superoxide and the hydroxyl radicals and it can chelate the transition metals [5]. Bilirubin reacts with diazotized sulfanilic acid in acidic medium to form pink colored azobilirubin with absorbance directly proportional to bilirubin concentration [2]. Bilirubin formed from hemoglobin breakdown and its role is an antioxidant and to correlate bilirubin-bin with uric acid to examine oxidant-antioxidant status of these parameters in breast cancer women [3]. Breast cancer is most killing disease and common problem in women especially young women [4]. In present study we have estimated serum uric acid and bilirubin in serum of breast cancer patients and in healthy subjects to assess the utility of these parameters in early diagnosis and medical management of breast cancer disease in women.

MATERIAL & METHODOLOGY

The Present study was conducted at Geetanjali medical college and hospital, Udaipur, Rajasthan from May 2014 to June 2015. 50 cases were diagnosed clinically and histo pathologically between ages 20-70 years of breast cancer women. All cases of breast lumps which were send for cytological examination underwent fine needle aspiration cytology (FNAC) proven both benign and malignant cancer were included in the present study. Malignant lesions were confirmed by subsequent mastectomy. Disease of other origin then breast cancer was excluded from the study. Normal healthy control subjects of age between 20-70 years were also included in our study. FNAC smear were fixed in methanol and stained by Giemsa stain. Serum separated from blood of study subjects then uric acid bilirubin estimated and levels were by spectrophotometer method in semi automated auto analyzer. Serum Uric acid was estimated by uricase method and serum bilirubin was estimated by Diazotized sulfanilic acid, Data obtained was analyzed statistically by calculating p-value by using online student t-test calculator.

RESULTS

The Mean concentration of serum uric acid in breast cancer group (Test) is 8.6 + 1.3 mg/dl as compared to 8.6 + 1.3 mg/dl in control group and the

difference among them found to be highly significant.(p-value <0.05).Similarly the concentration of serum bilirubin in breast cancer group(Test) is 0.93 + 1.4 mg/dl as compared to 0.86 + 2.6 mg/dl in control group but the difference among them is not found significant.(p-value 0.86).

Table-1. Age wise distribution of participant				
Group	Number(n)	Age Group(yr)	Mean Age	
Test	50	20-70	38.31+ 3.2	
Control	50	20-70	34.53 + 4	

Table-1:	Age	wise	distribution	of	participant

Table 2: Mean concentration	n of S.bilirubin	and S.Uric acid in	both group
-----------------------------	------------------	--------------------	------------

Tuble 21 filean concentration of Storm abin and Storife acta in Soun Broup					
Group		Number(n)	Test Group	Control Group	P-value
S.Uric	Acid	50	8.6 + 1.3	4.9 + 1.6	<0.05
(mg/dl)					
(mean+S.D.)					
S.Bilirubin(n	ng/dl)	50	0.93 + 1.4	0.86 + 2.6	0.8672
Mean+S.D.)	-				




Fig-1: Graphical presentation of various parameters between Test and control group

DISCUSSION

In present study serum uric acid levels increased then healthy control subjects that is similar to reported by other studies and showed that uric acid level may be a protective agent and its functions as antioxidant and elevated serum uric acid risk factor for cancer incidence and mortality in breast cancer of women [8-11]. According to G. Krishna et al.; [8] a significant rise in uric acid level in untreated women of breast cancer patients, which may be due to high oxidative stress. In our studies the serum bilirubin level in breast carcinoma women were found to be within normal limits and compared with bilirubin level of healthy control group of breast carcinoma women, it showed insignificant correlation. We have compared bilirubin level in subjects of breast carcinoma reported by other workers, similar results were obtained [9-13]. However Jeime Kepitulnik 2004 reported correlation of bilirubin and oxidative stress due to carcinogenesis in breast carcinoma of women. Antioxidant like uric acid and bilirubin may be important in determining the oxidant and antioxidant status in breast cancer. In the etiology of cancer involvement of oxidant such as hydrogen peroxide (H_2O_2), singlet oxygen ($\frac{1}{2}O_2$) and superoxide anion (O₂) and hydroxyl radicals (OH) are important and well documented in literature [13].

CONCLUSION

In present study we concluded that increase level of serum uric acid may be due to its protective role in response to increased oxidative stress. The level of bilirubin in normal range may be due to bilirubin scavenge during oxidative load or oxidative stress in breast carcinoma women.

REFRENCES

- 1. Umesh Kumar Pareek, Avdhesh Kumar Sharma, Ashwati Nair, Ketan Mangukiya, Mrs. Neha Sharma, K. L. Mali; Comparative study of level of uric acid in type 2 Diabetes mellitus associated with hypertension, IJSN, 2014; 5 (4): 622-625.
- White Abraham, Handler Philip, Smith Emile L, 2. Hill Robert L, Lehman Robert L; in Principles of

Biochemistry 6th Ed., Tata Mc Graw Hill Publishing Company Limited, New Delhi, 2004.

- 3. Faruk Tas, Hansel H, Belce A, IIvan S, Argon A, Camlica H, Topaz E; Oxidative stress in breast cancer. Med Oncal, 2005; 22 (1): 11-115.
- 4. Abdulla M Jarai, Jagannadha Rao Peela, Shakila Srikumar, Ibrahim Athetalla, Salid Omar Alsoaliti, Hayam E, Aalami, Farag Elsaari; Role of serum uric acid in carcinoma breast in Lybian patients. Asian academic research Journal of Multi discipilinary, 2011; 14-15.
- 5. Shish M. Kawthalkar; Essential of Clinical Pathology, J.P. Brothers publications New Delhi, 2010.
- 6. Trivedi RC, Reber L, Berta E, Stong L; New enzymatic method for serum uric acid at 500 mm. Clin Chem 1978; 24(2): 1908-1911.
- Winsten S, Cehelyk BA; Rapid Micro Diazo technique for measuring total bilirubin. Clin Chem Acta, 1969; 25: 441-446.
- 8. Kang D; Oxidative stress, DNA damage and breast cancer" AACN Clin issues, 2002; 540-549.

- Krishna Veni G, Bhaskar Rao D, Muni Kumar D, Usha B, Murli Krishna V, Raghava Roa T; Clinical evaluation of oxidative stress in women with breast cancer. Recent research in science Technology, 2011; (3): 55-58.
- 10. Sedlak Thomas W, Synder SH; Bilirubin benefits, cellular protection by a biliverdin reductase antioxidant cycle. Paediatrics 2004; 113; 1776-1782.
- 11. Jamie Kepitulnik; Bilirubin. An endogenous products of Heme degradation with both cytotoxic and cyto protective properties. Mol Pharmacol 2004; 66: 773-779.
- Huange XL, Sheu JY, Lin Th; Association between oxidative stress and changes of trace elements in patients with breast cancer. Clinical Biochemistry, 1999; 32: 131-136.
- 13. Fisher SM, Floyd RA, Cope-land ES; Workshop grants. National Institute of Health. Oxy radicals in carcinogenesis a chemical pathology study section workshop. Cancer Res, 1983; 43; 5631-5634.